Improvement of H5N1 influenza vaccine viruses: Influence of internal gene segments of avian and human origin on production and hemagglutinin content

Vaccine

Volumn 29, Issue 32, 2011, Pages 5153-5162

  Abt, Marion ^a,d   de Jonge, Jørgen ^b   Laue, Michael ^a,c   Wolff, Thorsten ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

H5N1; Influenza virus; Reverse genetics; Vaccine

Indexed keywords

COMPLEMENTARY DNA; DETERGENT; DNA DIRECTED RNA POLYMERASE; ETHER; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS HEMAGGLUTININ; VIRUS MORPHOGENIC PROTEIN; VIRUS PROTEIN; VIRUS RNA; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHICKEN; CONTROLLED STUDY; DEGLYCOSYLATION; EMBRYO; FEMALE; FERRET; GENETIC REASSORTMENT; HEMAGGLUTININ GENE; HUMAN; HUMAN CELL; IMMUNOGOLD ELECTRON MICROSCOPY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N1; M GENE; NEURAMINIDASE GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PB1 GENE; PLASMID; PRIORITY JOURNAL; PROTEIN CONTENT; VACCINE PRODUCTION; VIRION; VIROGENESIS; VIRUS GENE; VIRUS LOAD; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; CHICK EMBRYO; CHICKENS; FEMALE; FERRETS; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICROSCOPY, ELECTRON; REASSORTANT VIRUSES; VACCINES, SYNTHETIC;

EID: 79960331581     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.036     Document Type: Article

References (40)

1. Malik Peiris J.S. Avian influenza viruses in humans. Revue Scientifique et Technique 2009, 28(April (1)):161-173.
2. Wong S.S., Yuen K.Y. Avian influenza virus infections in humans. Chest 2006, 129(January (1)):156-168.
3. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New England Journal of Medicine 2009, 360(25):2605-2615.
4. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459(June (7249)):931-939.
5. Kilbourne E.D., Murphy J.S. Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. The Journal of Experimental Medicine 1960, 111(March):387-406.
6. Beare A.S., Kendal A.P., Cox N.J., Scholtissek C. Human trials with wild-type H1N1 and recombinant H3N2-H1N1 influenza A viruses of 1977-1978. Infection and Immunity 1980, 28(June (3)):753-761.
7. Beare A.S., Schild G.C., Craig J.W. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet 1975, 2(October (7938)):729-732.
8. Bardiya N., Bae J.H. Influenza vaccines: recent advances in production technologies. Applied Microbiology and Biotechnology 2005, 67(May (3)):299-305.
9. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(May (11)):6108-6113.
10. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(August (16)):9345-9350.
11. Fodor E., Devenish L., Engelhardt O.G., Palese P., Brownlee G.G., Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. Journal of Virology 1999, 73(November (11)):9679-9682.
12. Lina B., Fletcher M.A., Valette M., Saliou P., Aymard M. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the european community for immunogenicity, in children, adults and the elderly. Biologicals 2000, 28(2):95-103.
13. Beyer W.E., Palache A.M., Osterhaus A.D. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clinical Drug Investigation 1998, 15(1):1-12.
14. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(May (9523)):1657-1664.
15. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(September (9540)):991-997.
16. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 2006, 354(March (13)):1343-1351.
17. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23(April (22)):2943-2952.
18. Stephenson I., Gust I., Pervikov Y., Kieny M.P. Development of vaccines against influenza H5. The Lancet Infectious Diseases 2006, 6(August (8)):458-460.
19. Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S., Engelhardt O.G. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008, 26(December (51)):6550-6554.
20. Partridge J., Kieny M.P. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010, 28(July (30)):4709-4712.
21. Bucher D., Popple S., Baer M., Mikhail A., Gong Y.F., Whitaker C., et al. M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. Journal of Virology 1989, 63(September (9)):3622-3633.
22. Ali A., Avalos R.T., Ponimaskin E., Nayak D.P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. Journal of Virology 2000, 74(September (18)):8709-8719.
23. Zhang J., Lamb R.A. Characterization of the membrane association of the influenza virus matrix protein in living cells. Virology 1996, 225(2):255-266.
24. McCown M.F., Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. Journal of Virology 2005, 79(March (6)):3595-3605.
25. McCown M.F., Pekosz A. Distinct domains of the influenza A virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. Journal of Virology 2006, 80(August (16)):8178-8189.
26. Ottmann M., Bergeron C., Valette M., Lina B. Genetic content of influenza H3N2 vaccine seeds. PLOS Currents Influenza 2010, August:RRN1165.
27. Zielecki F., Semmler I., Kalthoff D., Voss D., Mauel S., Gruber A.D., et al. Virulence determinants of avian H5N1 influenza A virus in mammalian and avian hosts: the role of the C-terminal ESEV motif in the viral NS1 protein. Journal of Virology 2010, August.
28. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 1938, 27(May (3)):493-497.
29. Sawai T., Itoh Y., Ozaki H., Isoda N., Okamoto K., Kashima Y., et al. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 2008, 124(June (2)):155-165.
30. WHO Production of pilot lots of inactivated influenza vaccine in response to a pandemic threat: an interim biosafety risk assessment. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2003, 78(November (47)):405-408.
31. Bourmakina S.V., Garcia-Sastre A. Reverse genetics studies on the filamentous morphology of influenza A virus. The Journal of General Virology 2003, 84(March (Pt 3)):517-527.
32. Bourmakina S.V., Garcia-Sastre A. The morphology and composition of influenza A virus particles are not affected by low levels of M1 and M2 proteins in infected cells. Journal of Virology 2005, 79(June (12)):7926-7932.
33. Roberts P.C., Lamb R.A., Compans R.W. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology 1998, 240(January (1)):127-137.
34. WHO. Global pandemic influenza action plan to increase vaccine supply; 2006. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_1/en/index.html.
35. Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., et al. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. Journal of Virology 2006, 80(June (11)):5233-5240.
36. Wanitchang A., Kramyu J., Jongkaewwattana A. Enhancement of reverse genetics-derived swine-origin H1N1 influenza virus seed vaccine growth by inclusion of indigenous polymerase PB1 protein. Virus Research 2010, 147(January (1)):145-148.
37. Rudneva I.A., Timofeeva T.A., Shilov A.A., Kochergin-Nikitsky K.S., Varich N.L., Ilyushina N.A., et al. Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants. Archives of Virology 2007, 152(6):1139-1145.
38. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305(January (1)):192-200.
39. Horimoto T., Murakami S., Muramoto Y., Yamada S., Fujii K., Kiso M., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 2007, 366(September (1)):23-27.
40. Adamo J.E., Liu T., Schmeisser F., Ye Z. Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. Journal of Virology 2009, 83(May (9)):4023-4029.